Axel Benner

Research Topics

• Time to event data analysis
• Statistics for high-dimensional covariate space
• Clinical statistics

 

Education

Diploma in Statistics, University of Dortmund 1978-1986

 

Other Experience and Professional Memberships

• International Biometric Society (IBS)
• International Society for Clinical Biostatistics (ISCB)

• Reviewer for Journal of Clinical Oncology, Statistics in Medicine, Biometrical Journal, Computational Statistics & Data Analysis, Bioinformatics and others

• Member of the "High-dimensional data" topic group of the STRATOS initiative
• Member of the Extended Board of the German Speaking Myeloma Multicenter Group (GMMG)
• Lead Biometrician of the German AML Study Group (AMLSG) and the German Speaking Myeloma Multicenter Group (GMMG)

Publication list (10 most relevant; last 5 years)

1. Edelmann D, Terzer T, Horak P, Schlenk R, Benner A. The Progression-Free-Survival Ratio in Molecularly Aided Tumor Trials: A Critical Examination of Current Practice and Suggestions for Alternative Methods. Biom J. 2025; 67(1): e70028.
2. Cocciardi S, Saadati M, Weiß N, Späth D, Kapp-Schwoerer S , Schneider I, et al. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. Hemasphere. 2025; 9(1): e70060.
3. Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. J Clin Oncol. 2024: JCO2402266.
4. Schreck N, Slynko A, Saadati M, Benner A. Statistical plasmode simulations–Potentials, challenges and recommendations. Statistics in Medicine. 2024; 43(9): 1804-1825.
5. Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024; 11(2): e101-e113.
6. Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023; 10(7): e495-e509.
7. Rahnenführer J, De Bin R, Benner A, Ambrogi F, Lusa L, Boulesteix AL, Migliavacca E, Binder H, Michiels S, Sauerbrei W, McShane L. Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges. BMC Med. 2023; 21(1).
8. Edelmann D, Welchowski T, Benner A. A consistent version of distance covariance for right-censored survival data and its application in hypothesis testing. Biometrics. 2022; 78(3): 867-879.
9. Arsov C, Albers P, Herkommer K, Gschwend J, Imkamp F, Peters I, Kuczyk M, et al. A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial. Int J Cancer. 2022; 150(11):1861-1869.
10. Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, et al. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022; 36(1): 90-99.